Proposal for descriptors and categories to include long-acting technologies to the MPP long-acting technologies repository

Owners of a given technology would be requested to fill in this proposed form in order to include their platform technology in the repository. We would like to kindly request your feedback to improve this questionnaire, as it will also be used to define the structure of the LA technologies repository. We thank you in advance for your time and effort.

Once finalised, the form will be appropriately formatted to allow box-checking.

1/ Technology name

………………………

2/ Technology main developer(s)

……………………..

3/ Health Applications

What health areas are you targeting with your technology?

- Disease agnostic
- HIV
- HCV
- HBV
- TB
- Malaria
- COVID-19
- Contraception
- Multipurpose technology (please specify) .....................
- Other(s): please specify ....................

Comments: ......................................

4/ Technology description

Please provide a description of the technology in one sentence

.................................................

5/ Route(s) of administration

What are the possible routes for administration for a medicine using your technology?

- Oral
- Subcutaneous
- Intramuscular
- Transdermal
- Vaginal
- Intravenous
- Other(s): (please specify) .....................

Comments: .................................
6/ Categorisation of the technology

To help us group the technologies and tag them to facilitate searches, please select the description(s) that best fit(s) your technology:

- Injectables
  - Carrier-enabled injectables
    - Silica nanoparticles
    - Polymer-based
    - Based on other nanoparticles
  - Non-carrier enabled injectables
    - In-situ forming gel
    - Oil depot
    - Micellar suspension
    - Aqueous suspension
    - Solid drug nanoparticles

- Non-injectables
  - Implantables
    - In-situ forming implant
    - Polymeric implant
    - EVA-matrix implant
    - Osmotic pump implant
    - Titanium implant
  - Non-implantable (devices)
    - Intra-vaginal ring
    - Microneedle patch
    - Gastric resident system (incl. osmotic pumps)
    - External pump

Comment:…………………….

7/ Other features of the technology

Tick all that apply

- Biodegradable
- Drug-eluting
- Removable
- Non-removable
- Refillable
- Single-use
- 3d-printed
- Molded
- Reservoir-type
- Monolithic
- Requires batteries
- Requires stimuli from outside the body

Other:…………………….
8/ API(s) compatibility

8a/ What are the desires features / special requirements of an API to be compatible with the technology?
   - Water-soluble molecules
   - Water-insoluble molecules
   - Small molecules
   - Nucleic acids
   - Proteins

   Comments or examples: ........................................

8b/ Loading: What is the maximum drug quantity to be loaded?
Please provide concentration or range : ...............  

8c/ Is it possible to deliver various drugs in the same administration?
   - Yes
   - No

   Comments: ........................................

9/ Product candidates

9a/ Could you disclose any therapeutic agents that have been successfully matched with your technology?

If possible, please provide drugs (and combinations of drugs) names, classes, indications, available data on administration, duration of action, and any public information on the development status:

<table>
<thead>
<tr>
<th>Name of drug</th>
<th>Class</th>
<th>Indication</th>
<th>Foreseen duration between administrations</th>
<th>Foreseen user group(s)</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9b/ For the provided therapeutic agents, if possible, please provide further information on the development and regulatory status when possible:

<table>
<thead>
<tr>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Additional comments (applications to SRA, provisional patents filed, tox data availability, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10/ **Technology main components**

*What are the main components of the technology (if applicable)?*

…………………………………..

11/ **Excipients**

*Are proprietary excipients used?*

- Yes
- No

Comments: ..............................

12/ **Technology competitive advantages**

*Please list any outstanding features of the technology. A few examples are listed. Feel free to include other characteristics of the technology. You could provide any supporting information in the last question.*

- Ease of administration (Comment:......)
- Frequency of administration (Comment:......)
- Release properties *in vivo* (Comment:......)
- Safety (Comment:......)
- Raw materials availability/price (Comment:......)
- Injectableability (if applicable) (Comment:......)
- Versatility (Comment:......)
- User acceptance (Comment:......)
- Storage and cold-chain related features (Comment:......)
- Targeted user groups (Comment:......)
- Scale-up prospects (Comment:....)

Other characteristics and comments: ..............................

13/ **Patents landscape**

*Please list patent families relevant to your technology and its applications*

..............................

14/ **Partnerships and sponsors**

*Please list any publicly available partnerships or sponsors*

..............................

15/ **Additional resources**

Publications, presentations, links, clinical trials resources, or other material that you would like to share via the repository or link to

..............................

*Thank you for taking the time to complete this questionnaire! We will use the provided information to include your technology in the MPP long-acting technologies repository.*

*Do you have any additional comments? ..............................